Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials

被引:25
|
作者
Landewe, Robert B. M. [1 ,2 ]
Connell, Carol A. [3 ]
Bradley, John D. [3 ]
Wilkinson, Bethanie [3 ]
Gruben, David [3 ]
Strengholt, Sander [4 ]
van der Heijde, Desiree [5 ]
机构
[1] Amsterdam Rheumatol Ctr, Amsterdam, Netherlands
[2] Atrium Med Ctr, Heerlen, Netherlands
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Inc, Capelle Aan Den Ijssel, Netherlands
[5] Leiden Univ, Med Ctr, Leiden, Netherlands
关键词
Modified total Sharp score; Missing data; Outlier; Prognostic factors; Radiographic progression; Rheumatoid arthritis; Tofacitinib; Sensitivity analyses; PROGNOSTIC-FACTORS; DOUBLE-BLIND; PATIENT CHARACTERISTICS; RISK MODEL; METHOTREXATE; MATRIX; MULTICENTER; INHIBITION; PREDICTION; ONSET;
D O I
10.1186/s13075-016-1106-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The detection of statistically significant reductions in radiographic progression during clinical studies in patients with rheumatoid arthritis (RA) has become increasingly difficult over the past decade due to early-escape study designs and declining rates of progression in control-group patients. We investigated the impact of extremes of radiographic data (outliers) and baseline prognostic factors on detection of treatment effects, to provide guidance on future analysis of joint structural data in RA clinical trials. Methods: Data were from two, phase 3, randomized, double-blind, placebo-controlled trials of tofacitinib in adult patients with moderate to severe RA: ORAL Scan (NCT00847613) and ORAL Start (NCT01039688). These studies detected significant reductions in radiographic progression with tofacitinib 10 mg twice daily (BID) plus background methotrexate (ORAL Scan), and with tofacitinib 5 or 10 mg BID as monotherapy (ORAL Start). We evaluated mean changes from baseline in van der Heijde modified total Sharp score (mTSS) at month 6 and month 12, using analysis of covariance (ANCOVA). A trimmed analysis was used to deal with extremes of data. The impact of baseline prognostic factors on radiographic progression was evaluated using ANCOVA to analyze the mean change from baseline in mTSS for each factor in turn. Results: The analysis included data from 720 patients from ORAL Scan and 880 patients from ORAL Start. Trimmed analyses were unbiased for the true mean estimate and enabled us to remove the effect of influential extreme observations in the data set. Almost all patients had at least one poor prognostic factor at baseline (e.g., high level of disease activity, or positive for rheumatoid factor). The strongest predictor of treatment effect was the severity of radiographic damage at baseline. Conclusions: A trimmed analysis can establish whether any significant inhibition of structural damage is being driven by extremes of data, and should be one of the sensitivity analyses of choice for structural data in RA clinical trials. Furthermore, analysis of radiographic data based on baseline prognostic factors may reveal increased treatment effects. Application of these methods to analysis of radiographic data from clinical trials in patients with RA, allows a more complete interpretation of data.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials
    Robert B. M. Landewé
    Carol A. Connell
    John D. Bradley
    Bethanie Wilkinson
    David Gruben
    Sander Strengholt
    Désirée van der Heijde
    Arthritis Research & Therapy, 18
  • [2] RADIOGRAPHIC PROGRESSION IN MODERN RA TRIALS IS STILL A ROBUST OUTCOME: RESULTS OF COMPREHENSIVE SENSITIVITY ANALYSIS IN TWO PHASE 3 TRIALS WITH TOFACITINIB
    van der Heijde, D.
    Connell, C.
    Bradley, J.
    Gruben, D.
    Strengholt, S.
    Landewe, R. B.
    ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 737 - 737
  • [3] Radiographic progression in clinical trials in rheumatoid arthritis: a systemic literature review of trials performed by industry
    Park, Yune-Jung
    Gherghe, Ana Maria
    van der Heijde, Desiree
    RMD OPEN, 2020, 6 (02):
  • [4] From inhibition of radiographic progression to maintaining structural integrity: a methodological framework for radiographic progression in rheumatoid arthritis and psoriatic arthritis clinical trials
    Landewe, Robert
    Strand, Vibeke
    van der Heijde, Desiree
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (07) : 1113 - 1117
  • [5] Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
    Kim, Joon Wan
    Choi, In Ah
    Lee, Eun Young
    Song, Yeong Wook
    Lee, Eun Bong
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2013, 28 (08) : 1134 - 1138
  • [6] Is radiographic progression a realistic outcome measure in clinical trials with early inflammatory arthritis?
    Landewé, R
    van de Heijde, D
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2003, 21 (05) : S37 - S41
  • [7] GLUCOCORTICOID EFFECT ON RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS BIOLOGICS TRIALS
    Boers, M.
    Aletaha, D.
    Mela, C. M.
    Smolen, J. S.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 961 - 962
  • [8] RADIOGRAPHIC PROGRESSION IN RHEUMATOID-ARTHRITIS - RESULTS OF 3 COMPARATIVE TRIALS
    VANRIEL, PLCM
    VANDERHEIJDE, DMFM
    NUVERZWART, IH
    VANDEPUTTE, LBA
    JOURNAL OF RHEUMATOLOGY, 1995, 22 (09) : 1797 - 1799
  • [9] Digital assessment of radiographic progression in clinical trials of rheumatoid arthritis Inter-reader Agreement
    Wu, C
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S344 - S344
  • [10] Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials
    Boers, Maarten
    Aletaha, Daniel
    Mela, Christopher M.
    Baker, Daniel G.
    Smolen, Josef S.
    JOURNAL OF RHEUMATOLOGY, 2016, 43 (06) : 1024 - 1026